A Model in which Hsp90 Targets Protein Folding Clefts: rationale for a New Approach to Neuroprotective Treatment of Protein Folding Diseases

摘要

In an EBM Minireview published in 2010, we proposed that the Hsp90/Hsp70-based chaperone machinery played a major role in determining the selection of proteins that have undergone oxidative or other toxic damage for ubiquitination and proteasomal degradation (). The proposal was based on a model in which the Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts (). The model provides a framework for thinking about the development of neuroprotective therapies for protein folding diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD) and the polyglutamine expansion disorders, such as Huntington’s disease (HD) and spinal and bulbar muscular atrophy (SBMA). Major aberrant proteins that misfold and accumulate in these diseases are ‘client’ proteins of the abundant and ubiquitous stress chaperone Hsp90 (). These Hsp90 client proteins include tau (AD), α-synuclein (PD), huntingtin (HD) and the expanded glutamine androgen receptor (polyQ AR) (SBMA). In this minireview we update our model in which Hsp90 acts on protein folding clefts and show how it forms a rational basis for developing drugs that promote the targeted elimination of these aberrant proteins.